Tagged with Lundbeck

France Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience.   We are the only specialty pharma player exclusively dedicated to neuroscience and it is important that this shines through in our dealings…

Malaysia Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to healthcare professionals and patients in the country. He also highlights his future plans for the affiliate to bring more innovative…

Turkey Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and experience from former periods of economic fluctuation to push the Turkish healthcare and life sciences sector forward.   Turkey made…

Turkey From collaborating with authorities to tackling awareness surrounding mental illnesses, Altan Gorseval, country manager of Lundbeck Turkey, paints an accurate picture of the company’s dedication to improving mental health and patient outcomes in the country. What have been your strategic priorities for Lundbeck Turkey over the past two years? Our…

UK Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.…

Poland Wojciech Koziejowski, managing director of Lundbeck Poland, discusses attaining reimbursement in Poland for the first time in ten years and the recent set-up of their global shared service center of more than 200 staff in Krakow. Moreover, he highlights the leading role the company is taking in educating key stakeholders…

Brazil Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he identifies to further increase awareness and improve market access in the mental health area. You took over the helm of…

Canada Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for mental illnesses; Lundbeck’s commitment to supporting patient associations in order to reduce the stigma associated with mental health conditions; and…

Slovakia Lundbeck Slovakia Country Manager, Svatopluk Betina, reflects on the performance of one of the most innovative pharmaceutical firms in the region and the challenges companies face when introducing new products to the market Can you please provide an overview of Lundbeck’s presence in Slovakia and share with our audience the…

Pharma Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit the patient. Lifestyle related illnesses are a major problem in Mexico, with 13 million people suffering from diabetes and 71…

Pharma Giulio Volpe, Managing Director of Lundbeck’s Italian API’s production plant, discusses what is leading multinational companies to relocate their production to Italy, the value the Italian plant can offer the Lundbeck group and the future of API production in Italy. Could you start off with a brief overview of the…

R&D Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep knowledge of CNS, how would you assess the Turkish medical systems’ ability to handle mental illness? First of all, when…